{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:57:37Z","timestamp":1785254257232,"version":"3.55.0"},"reference-count":40,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>Diagnosis and accurate localization of recurrent tumors in Cushing\u2019s disease (CD) are challenging, especially after multiple transsphenoidal surgeries (TSSs) or radiosurgery. Even experts face difficulties in detecting these recurrent tumors, and a favorable surgical outcome is not guaranteed. In this report, the authors aimed to determine the usefulness of <jats:sup>11<\/jats:sup>C-methionine positron emission tomography (MET-PET) for evaluating patients with recurrent CD with inconclusive magnetic resonance imaging (MRI) lesions and to develop a treatment protocol for these cases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>In this retrospective study of patients with recurrent CD in the period between April 2018 and December 2022, the authors assessed the usefulness of MET-PET in determining whether equivocal MRI findings were recurrent tumors or postsurgical cavities and deciding further treatment options. All patients had undergone at least one TSS, and most had undergone multiple TSSs and had pathologically confirmed corticotroph tumors with hypercortisolemia.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>Overall, 15 patients with recurrent CD (10 females and 5 males) were included, all of whom had undergone MET-PET. All patients had been subjected to multiple treatments, including TSSs or radiosurgeries. Their MRI scans demonstrated less-enhanced lesions that were not confirmed as recurrences even with cutting-edge MRI because they could not be distinguished from postsurgical changes with confidence. MET uptake was positive in 8 patients (9 examinations) and negative in 7. Following MET-PET, repeat TSS was performed in 5 patients. Corticotroph tumors were identified in all 5 patients, even though one of them had negative MET uptake. The MET uptake precisely identified a tumor location on the opposite side of the MRI-suspected lesion in 2 patients. Meanwhile, patients with negative uptake and mild hypercortisolism were only observed. Nonsurgical options were also used in other patients: temozolomide (TMZ) was administered in 2 patients owing to a prior history of multiple TSSs and radiosurgery and the drug-resistant nature of the disease. TMZ was highly effective in these patients; their Cushing\u2019s symptoms ameliorated, and their adrenocorticotropic hormone and cortisol levels continued to decline. Interestingly, MET uptake disappeared following TMZ treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CONCLUSIONS<\/jats:title>\n<jats:p>MET-PET is extremely useful for confirming equivocal lesions on MRI in patients with recurrent CD and for deciding further treatment options. The authors propose a novel protocol based on MET-PET results for treating patients with relapsing CD in whom the recurrent tumors cannot be confirmed with MRI.<\/jats:p>\n<\/jats:sec>","DOI":"10.3171\/2023.5.jns23179","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T06:13:36Z","timestamp":1688192016000},"page":"1671-1680","source":"Crossref","is-referenced-by-count":17,"title":["Clinical decision-making based on 11C-methionine PET in recurrent Cushing\u2019s disease with equivocal MRI findings"],"prefix":"10.3171","volume":"139","author":[{"given":"Atsushi","family":"Ishida","sequence":"first","affiliation":[{"name":"Hypothalamic and Pituitary Center, Moriyama Memorial Hospital, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging & Nuclear Medicine, Tokyo Women\u2019s Medical University, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryogo","family":"Minamimoto","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine, National Center for Global Health and Medicine, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Hotta","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine, National Center for Global Health and Medicine, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Inoshita","sequence":"additional","affiliation":[{"name":"and Departments of Pathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takano","sequence":"additional","affiliation":[{"name":"Endocrinology, Moriyama Memorial Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Hypothalamic and Pituitary Center, Moriyama Memorial Hospital, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"5","key":"b1","series-title":"Neurosurgery","first-page":"775","article-title":"Resection of the cavernous sinus medial wall improves remission rate in functioning pituitary tumors: retrospective analysis of 248 consecutive cases","volume":"91","author":"Ishida A","year":"2022","unstructured":"Ishida A, Shiramizu H, Yoshimoto H,  Resection of the cavernous sinus medial wall improves remission rate in functioning pituitary tumors: retrospective analysis of 248 consecutive cases. Neurosurgery. 2022;91(5):775\u2013781."},{"issue":"6","key":"b2","series-title":"Neurosurg Rev","first-page":"3675","article-title":"Exoscopic vs. microscopic transsphenoidal surgery for Cushing\u2019s disease: a retrospective single-center study on 388 patients","volume":"45","author":"Sumis\u0142awski P","year":"2022","unstructured":"Sumis\u0142awski P, Piffko A, Huckhagel T,  Exoscopic vs. microscopic transsphenoidal surgery for Cushing\u2019s disease: a retrospective single-center study on 388 patients. Neurosurg Rev. 2022;45(6):3675\u20133681."},{"issue":"1","key":"b3","series-title":"J Clin Endocrinol Metab","first-page":"205","article-title":"Diagnostic pitfalls in Cushing disease: surgical remission rates, test thresholds, and lessons learned in 105 patients","volume":"107","author":"Mallari RJ","year":"2022","unstructured":"Mallari RJ, Thakur JD, Barkhoudarian G,  Diagnostic pitfalls in Cushing disease: surgical remission rates, test thresholds, and lessons learned in 105 patients. J Clin Endocrinol Metab. 2022;107(1):205\u2013218."},{"key":"b4","series-title":"Front Oncol","first-page":"810234","article-title":"Transsphenoidal surgery of corticotroph adenomas with cavernous sinus invasion: results in a series of 86 consecutive patients","volume":"12","author":"Dai C","year":"2022","unstructured":"Dai C, Feng M, Lu L,  Transsphenoidal surgery of corticotroph adenomas with cavernous sinus invasion: results in a series of 86 consecutive patients. Front Oncol. 2022;12:810234."},{"key":"b5","series-title":"Front Horm Res","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000091580","article-title":"Treatment of Cushing\u2019s disease: a retrospective clinical study of the latest 100 cases","volume":"34","author":"Hofmann BM","year":"2006","unstructured":"Hofmann BM, Fahlbusch R. Treatment of Cushing\u2019s disease: a retrospective clinical study of the latest 100 cases. Front Horm Res. 2006;34:158\u2013184."},{"issue":"5","key":"b6","series-title":"Pituitary","first-page":"595","article-title":"Outcomes of pituitary surgery for Cushing\u2019s disease: a systematic review and meta-analysis","volume":"23","author":"Stroud A","year":"2020","unstructured":"Stroud A, Dhaliwal P, Alvarado R,  Outcomes of pituitary surgery for Cushing\u2019s disease: a systematic review and meta-analysis. Pituitary. 2020;23(5):595\u2013609."},{"issue":"2","key":"b7","series-title":"Eur J Endocrinol","first-page":"283","article-title":"Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing\u2019s disease: care reality in the Munich Metropolitan Region","volume":"170","author":"Dimopoulou C","year":"2013","unstructured":"Dimopoulou C, Schopohl J, Rachinger W,  Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing\u2019s disease: care reality in the Munich Metropolitan Region. Eur J Endocrinol. 2013;170(2):283\u2013292."},{"issue":"12","key":"b8","series-title":"Endocr J","first-page":"1115","article-title":"Therapeutic outcomes in patients undergoing surgery after diagnosis of Cushing\u2019s disease: a single-center study","volume":"62","author":"Yamada S","year":"2015","unstructured":"Yamada S, Inoshita N, Fukuhara N,  Therapeutic outcomes in patients undergoing surgery after diagnosis of Cushing\u2019s disease: a single-center study. Endocr J. 2015;62(12):1115\u20131125."},{"issue":"1","key":"b9","series-title":"J Neurosurg","first-page":"9","article-title":"Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years","volume":"108","author":"Hofmann BM","year":"2008","unstructured":"Hofmann BM, Hlavac M, Martinez R, Buchfelder M, M\u00fcller OA, Fahlbusch R. Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg. 2008;108(1):9\u201318."},{"issue":"6","key":"b10","series-title":"Neurosurgery","first-page":"E1030","article-title":"Outcomes after repeat transsphenoidal surgery for recurrent Cushing disease: updated","volume":"85","author":"Burke WT","year":"2019","unstructured":"Burke WT, Penn DL, Repetti CS, Iuliano S, Laws ER. Outcomes after repeat transsphenoidal surgery for recurrent Cushing disease: updated. Neurosurgery. 2019;85(6):E1030\u2013E1036."},{"issue":"22","key":"b11","series-title":"J Clin Med","first-page":"6848","article-title":"Reoperation for recurrent and persistent Cushing\u2019s disease without visible MRI findings","volume":"11","author":"Wang B","year":"2022","unstructured":"Wang B, Zheng S, Ren J,  Reoperation for recurrent and persistent Cushing\u2019s disease without visible MRI findings. J Clin Med. 2022;11(22):6848."},{"issue":"2","key":"b12","series-title":"Eur J Nucl Med Mol Imaging","first-page":"169","article-title":"11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas","volume":"33","author":"Tang BN","year":"2006","unstructured":"Tang BN, Levivier M, Heureux M,  11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging. 2006;33(2):169\u2013178."},{"issue":"5","key":"b13","series-title":"Eur J Endocrinol","first-page":"485","article-title":"Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI","volume":"175","author":"Koulouri O","year":"2016","unstructured":"Koulouri O, Kandasamy N, Hoole AC,  Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. Eur J Endocrinol. 2016;175(5):485\u2013498."},{"issue":"4","key":"b14","series-title":"Eur J Endocrinol","first-page":"M107","article-title":"A role for 11C-methionine PET imaging in ACTH-dependent Cushing\u2019s syndrome","volume":"173","author":"Koulouri O","year":"2015","unstructured":"Koulouri O, Steuwe A, Gillett D,  A role for 11C-methionine PET imaging in ACTH-dependent Cushing\u2019s syndrome. Eur J Endocrinol. 2015;173(4):M107\u2013M120."},{"issue":"6","key":"b15","series-title":"Pituitary","first-page":"878","article-title":"Selective resection of cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET\/MRI","volume":"24","author":"Berkmann S","year":"2021","unstructured":"Berkmann S, Roethlisberger M, Mueller B,  Selective resection of cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET\/MRI. Pituitary. 2021;24(6):878\u2013886."},{"issue":"12","key":"b16","series-title":"Lancet Diabetes Endocrinol","first-page":"847","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu M","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I,  Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847\u2013875."},{"issue":"2","key":"b17","series-title":"Neurosurg Focus","first-page":"E16","article-title":"Update on the management of recurrent Cushing\u2019s disease","volume":"38","author":"Rutkowski MJ","year":"2015","unstructured":"Rutkowski MJ, Flanigan PM, Aghi MK. Update on the management of recurrent Cushing\u2019s disease. Neurosurg Focus. 2015;38(2):E16."},{"issue":"1","key":"b18","series-title":"Eur J Endocrinol","first-page":"G1","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot G","year":"2018","unstructured":"Raverot G, Burman P, McCormack A,  European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1\u2013G24."},{"key":"b19","series-title":"Front Endocrinol (Lausanne)","first-page":"650791","article-title":"Aggressive Cushing\u2019s disease: molecular pathology and its therapeutic approach","volume":"12","author":"Yamamoto M","year":"2021","unstructured":"Yamamoto M, Nakao T, Ogawa W, Fukuoka H. Aggressive Cushing\u2019s disease: molecular pathology and its therapeutic approach. Front Endocrinol (Lausanne). 2021;12:650791."},{"issue":"1","key":"b20","series-title":"Sci Rep","first-page":"15666","article-title":"11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: radiomics approach with random forest classifier","volume":"9","author":"Hotta M","year":"2019","unstructured":"Hotta M, Minamimoto R, Miwa K. 11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: radiomics approach with random forest classifier. Sci Rep. 2019;9(1):15666."},{"issue":"7","key":"b21","series-title":"PLoS One","first-page":"e0132515","article-title":"Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: visual assessment versus quantitative assessment","volume":"10","author":"Minamimoto R","year":"2015","unstructured":"Minamimoto R, Saginoya T, Kondo C,  Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: visual assessment versus quantitative assessment. PLoS One. 2015;10(7):e0132515."},{"issue":"11","key":"b22","series-title":"Mod Pathol","first-page":"1172","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante M","year":"2007","unstructured":"Volante M, Brizzi MP, Faggiano A,  Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20(11):1172\u20131182."},{"issue":"2","key":"b23","series-title":"Neurosurgery","first-page":"266","article-title":"Outcomes after repeat transsphenoidal surgery for recurrent Cushing\u2019s disease","volume":"63","author":"Patil CG","year":"2008","unstructured":"Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER Jr. Outcomes after repeat transsphenoidal surgery for recurrent Cushing\u2019s disease. Neurosurgery. 2008;63(2):266\u2013271."},{"issue":"2","key":"b24","series-title":"Best Pract Res Clin Endocrinol Metab","first-page":"101489","article-title":"The role of reoperation after recurrence of Cushing\u2019s disease","volume":"35","author":"Cardinal T","year":"2021","unstructured":"Cardinal T, Zada G, Carmichael JD. The role of reoperation after recurrence of Cushing\u2019s disease. Best Pract Res Clin Endocrinol Metab. 2021;35(2):101489."},{"issue":"5","key":"b25","series-title":"Pituitary","first-page":"713","article-title":"Pituitary surgery in Cushing\u2019s disease: first line treatment and role of reoperation","volume":"25","author":"Jones PS","year":"2022","unstructured":"Jones PS, Swearingen B. Pituitary surgery in Cushing\u2019s disease: first line treatment and role of reoperation. Pituitary. 2022;25(5):713\u2013717."},{"issue":"3","key":"b26","series-title":"Pituitary","first-page":"540","article-title":"Treatment of recurrent and persistent Cushing\u2019s disease after first transsphenoidal surgery: lessons learned from an international meta-analysis","volume":"25","author":"Perez-Vega C","year":"2022","unstructured":"Perez-Vega C, Ramos-Fresnedo A, Tripathi S,  Treatment of recurrent and persistent Cushing\u2019s disease after first transsphenoidal surgery: lessons learned from an international meta-analysis. Pituitary. 2022;25(3):540\u2013549."},{"issue":"4","key":"b27","series-title":"Neurosurgery","first-page":"949","article-title":"Repeat transsphenoidal surgery for the treatment of remaining or recurring pituitary tumors in acromegaly","volume":"67","author":"Yamada S","year":"2010","unstructured":"Yamada S, Fukuhara N, Oyama K, Takeshita A, Takeuchi Y. Repeat transsphenoidal surgery for the treatment of remaining or recurring pituitary tumors in acromegaly. Neurosurgery. 2010;67(4):949\u2013956."},{"issue":"3","key":"b28","series-title":"Clin Nucl Med","first-page":"e130","article-title":"Utility of 11C-methionine and 18F-FDG PET\/CT in patients with functioning pituitary adenomas","volume":"41","author":"Feng Z","year":"2016","unstructured":"Feng Z, He D, Mao Z,  Utility of 11C-methionine and 18F-FDG PET\/CT in patients with functioning pituitary adenomas. Clin Nucl Med. 2016;41(3):e130\u2013e134."},{"issue":"4","key":"b29","series-title":"J Neurosurg","first-page":"750","article-title":"Usefulness of composite methionine-positron emission tomography\/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma","volume":"112","author":"Ikeda H","year":"2010","unstructured":"Ikeda H, Abe T, Watanabe K. Usefulness of composite methionine-positron emission tomography\/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J Neurosurg. 2010;112(4):750\u2013755."},{"issue":"4","key":"b30","series-title":"J Nucl Med","first-page":"610","article-title":"PET as a tool in the clinical evaluation of pituitary adenomas","volume":"32","author":"Bergstr\u00f6m M","year":"1991","unstructured":"Bergstr\u00f6m M, Muhr C, Lundberg PO, L\u00e5ngstr\u00f6m B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med. 1991;32(4):610\u2013615."},{"issue":"3-4","key":"b31","series-title":"Neuroendocrinology","first-page":"205","article-title":"Positron emission tomography in acromegaly and other pituitary adenoma patients","volume":"83","author":"Muhr C","year":"2006","unstructured":"Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology. 2006;83(3-4):205\u2013210."},{"issue":"1","key":"b32","series-title":"BMC Cancer","first-page":"837","article-title":"The combination of 13N-ammonia and 11C-methionine in differentiation of residual\/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal adenomectomy","volume":"21","author":"Zhang F","year":"2021","unstructured":"Zhang F, He Q, Luo G,  The combination of 13N-ammonia and 11C-methionine in differentiation of residual\/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal adenomectomy. BMC Cancer. 2021;21(1):837."},{"issue":"8","key":"b33","series-title":"J Neuroendocrinol","first-page":"e13123","article-title":"Pituitary MRI in Cushing\u2019s disease\u2014an update","volume":"34","author":"Bonneville JF","year":"2022","unstructured":"Bonneville JF, Potorac I, Petrossians P, Tshibanda L, Beckers A. Pituitary MRI in Cushing\u2019s disease\u2014an update. J Neuroendocrinol. 2022;34(8):e13123."},{"key":"b34","series-title":"Front Endocrinol (Lausanne)","first-page":"1090144","article-title":"The clinical outcomes of imaging modalities for surgical management Cushing\u2019s disease \u2013 a systematic review and meta-analysis","volume":"13","author":"Koh CH","year":"2023","unstructured":"Koh CH, Khan DZ, Digpal R,  The clinical outcomes of imaging modalities for surgical management Cushing\u2019s disease \u2013 a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;13:1090144."},{"issue":"4","key":"b35","series-title":"Pituitary","first-page":"573","article-title":"11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy","volume":"25","author":"Bashari WA","year":"2022","unstructured":"Bashari WA, van der Meulen M, MacFarlane J,  11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. Pituitary. 2022;25(4):573\u2013586."},{"issue":"4","key":"b36","series-title":"Pituitary","first-page":"587","article-title":"Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery","volume":"25","author":"Bakker LEH","year":"2022","unstructured":"Bakker LEH, Verstegen MJT, Ghariq E,  Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary. 2022;25(4):587\u2013601."},{"issue":"11","key":"b37","series-title":"J Clin Endocrinol Metab","first-page":"E280","article-title":"Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression","volume":"95","author":"Bush ZM","year":"2010","unstructured":"Bush ZM, Longtine JA, Cunningham T,  Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95(11):E280\u2013E290."},{"issue":"2","key":"b38","series-title":"Endocrine","first-page":"218","article-title":"Recurrence after pituitary surgery in adult Cushing\u2019s disease: a systematic review on diagnosis and treatment","volume":"70","author":"Braun LT","year":"2020","unstructured":"Braun LT, Rubinstein G, Zopp S,  Recurrence after pituitary surgery in adult Cushing\u2019s disease: a systematic review on diagnosis and treatment. Endocrine. 2020;70(2):218\u2013231."},{"issue":"4","key":"b39","series-title":"Eur J Endocrinol","first-page":"593","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman P","year":"2022","unstructured":"Burman P, Trouillas J, Losa M,  Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol. 2022;187(4):593\u2013605."},{"issue":"4","key":"b40","series-title":"J Clin Endocrinol Metab","first-page":"e1816","article-title":"Molecular imaging targeting corticotropin-releasing hormone receptor for corticotropinoma: a changing paradigm","volume":"106","author":"Walia R","year":"2021","unstructured":"Walia R, Gupta R, Bhansali A,  Molecular imaging targeting corticotropin-releasing hormone receptor for corticotropinoma: a changing paradigm. J Clin Endocrinol Metab. 2021;106(4):e1816\u2013e1826."}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/139\/6\/article-p1671.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/139\/6\/article-p1671.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/139\/6\/article-p1671.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T10:44:18Z","timestamp":1716029058000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/139\/6\/article-p1671.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":40,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2023.5.jns23179","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}